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ABSTRACT. Starting from 3-amino-5-(2-hydroxyphenyl) amino acid coupled triazoles 1a-e, new 3-(2-
hydroxyphenyl)-3H-imidazo[2,1-c][1,2,4]triazol-6(5H)-one 2a,b, 3b,d, 6a and 3-N-arly(alkyl) amino acid coupled 
triazoles 4b,d, 7a,c,d,e have been synthesized as potential antileishmanial agents. The structures of the newly 
synthesized compounds were confirmed using elemental and spectral analyses (FT-IR, 1H-NMR, 13C-NMR and 
MS). The in vitro antileishmanial potency of the synthesized compounds was evaluated compared to 
Amphotericin B deoxycholate and miltefosine as lead references. Compounds 2b, 7d and 7e showed perfect IC50 
values corresponding to amphotericin B and more patent than miltefosine against L. aethiopica promastigotes. 
  




Leishmaniasis occurs as visceral, cutaneous, mucocutaneous and diffused mucocutaneous 
leishmaniasis and is caused by Leishmania genus and transmitted by bite of infected female 
sand fly [1]. Leishmania parasites have two basic life stages: an extracellular motile stage 
(promastigote) inside an invertebrate host and an intracellular non-motile stage (amastigote) 
inside a vertebrate host [2]. The common form of leishmaniasis is Cutaneous leishmaniasis (CL) 
which widely distributed all around the world [3]. Within the last decade, the treatment is 
limited to a few drugs, such as amphotericin B, miltefosine and paromomycin and far from 
satisfactory [4], although a broad array of species can be responsible to cause leishmaniasis, 
affecting humans and animals [6-11]. Miltefosine-resistant Leishmania donovani promastigotes 
also demonstrated modification in sterol biosynthesis and lipid compositions which influences 
the membrane fluidity and permeability and ultimately may affect drug-membrane interactions 
[5]. Other possible oral treatments for CL include azole antifungals that show in vitro [12] and 
in vivo activity against Leishmania [13–20]. Triazoles antifungals inhibit 14α-lanosterol 
demethylation, causing accumulation of 14α-methyl sterols blocking the synthesis of ergosterol, 
the main sterol of Leishmania such as fluconazole, eliminating promastigote and amastigote of 
Leishmania sp. as well as Trypanosoma cruzi, protozoa phylogenetically related to Leishmania 
[21]. 
In deeps, imidazo triazole moieties have been widely reported in the mainstream as well as 
in the patent literature [22-26], also demonstrated dual activity against leishmania [27, 28]. 
Therefore, as a part of our effort to use a simple and effective method for the synthesis of 




Melting points were determined in open-glass capillaries using a Griffin melting point apparatus 
and are all uncorrected. Infrared spectra (IR) were recorded on Perkin Elmer 1430 infrared 
spectrophotometer. 1H-NMR and 13C-NMR spectra were scanned on Jeol-400 MHz NMR-
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spectrometer (DMSO-d6) and chemical shifts are given in  (ppm) down field from 
tetramethylsilane (TMS) as internal standard. Micro analyses were performed on Vario El Fab-
Nr elemental analyzer. Following up of the reactions as performed by thin-layer 
chromatography (TLC) on silica gel (60GF254) coated Glass plates and the spots were 
visualized by exposure to iodine Vapors or UV-lamp at 254 nm for few seconds. 
 
General procedures for synthesis of compounds 2a,b and 3b,d  
 
Method A. To a solution of 2-amino-5(2-hydroxy phenyl)-1,2,4-triazole carboxylic acid  1a,b,d 
(0.01 mol) and chloroacetyl chloride (1.1 g, 0.01 mol) in acetonitrile, 2 g of potassium carbonate  
in 1 mL water was added as a base. The reaction mixture was refluxed for 5 h to complete the 
reaction (monitored by TLC). After completion of the reaction, the reaction mixture was cooled 
to room temperature and the solid mass was filtered off, washed with water and recrystallized 
from ethanol. 
 
Method B. To a solution of 2-amino-5(2-hydroxy phenyl)-1,2,4-triazole carboxylic acid  1b,d 
(0.01 mol) and chloroacetyl chloride (1.1 g, 0.01 mol) in chloroform and triethylamine as a 
catalyst. The reaction refluxed for 7 h to complete the reaction (monitored by TLC). After 
completion of the reaction, mixture was cooled to room temperature and the solid mass was 
filtered off and recrystallized from ethanol to give compounds 3b,d. 
 
3-(2-Hydroxyphenyl)-3H-imidazo[2,1-c][1,2,4]triazol-6(5H)-one 2a. Anal. calcd. for 
C10H8N4O2 (Mr = 216.20): C, 55.50; H, 3.70; N, 25.90. Found: C, 55.17; H, 3.39; N, 25.50.  IR 
(, cm-1); 3404 (broad O–H), 3038 (C–H) aromatic, 2991 (C–H) aliphatic, 1695 (C=O), 1590 
(C=N). 1H-NMR (400 MHz; d6-DMSO,  ppm); 3.92 (s, 2H, CH2), 3.99 (s, 1H, CH-triazole), 
6.89-7.89 (m, 4H, ArH), 11.31 (s, 1H, OH, disappeared by D2O),  
13CNMR : 38.62 (CH2), 74.17 
(CH-triazole), 114.95, 118.78, 126.58. 128.78, 134.66, 143.05 (ArC), 158.22 (C=N), 170.10 
(C=O). MS (m/z+, %): 215.20 (M-2, 0.1); 194.10 (100); 167.10 (21.12); 149.15 (24.99), 133.15 
(41.56); 120.10 (30.79); 91.10 (71.73); 65.05 (50.65). 
 
3-(2-Hydroxyphenyl)-3-methyl-3H-imidazo[2,1-c][1,2,4]triazol-6(5H)-one 2b. Anal. calcd. for 
C11H10N4O2 (Mr = 230.24): C, 52.56; H, 4.34; N, 24.32. Found: C, 52.26; H, 4.05; N, 24.01.IR 
(, cm-1); 3515 (broad O–H), 3010 (C–H) aromatic, 2991 (C–H) aliphatic, 1713 (C=O), 1227 
(Ph–O). 1H NMR (400 MHz; d6-DMSO, ppm); 2.43 (s 3H, CH3), 3.46 (s, 2H, CH2), 6.84-7.62 
(m, 4H, ArH), 15.42 (s, 1H, OH, disappeared by D2O),  
13CNMR : 14.11 (CH3), 37.62 (CH2), 




yl)propanoic acid 3b. Anal. calcd. for C14H16N4O4 (Mr = 304.30): C, 55.20; H, 5.26; N, 18.40. 
Found: C, 54.87; H, 5.10; N, 18.02.IR (, cm-1); 3408 (broad O–H), 3321 (O–H), 3136 (NH), 
3071 (C–H) aromatic, 2981 (C–H) aliphatic, 1714 (C=O), 1617 (COOasy), 1587 (COOsy), 1236 
(Ph–O). 1H NMR (400 MHz; d6-DMSO, ppm); 2.55 (S, 3H, CH3), 3.86 (d, 3H, CH3), 4.09 (s, 
1H, CH-COOH), 4.10 (s, 2H, CH2), 5.14 (s, 2H, OH, NH, disappeared by D2O), 6.91-7.66 (m, 
4H, ArH), 14.40 (s, 1H, OH, disappeared by D2O). 
13CNMR: 14.81 (CH3), 30.72 (CH3), 33.53 
(CH2), 34.01(CH), 117.47, 118.86, 126.22, 126.86, 128.87, 132.20 (ArC), 163.68 (C=N), 169.27 
(C=O), 174.13 (C=O).MS (m/z+, %): 305 (M+1, 2.95); 247 (4.81); 189.10 (6.39); 159.10 (3.70); 
117.15 (22.48), 59 (100). 
 
2-(2-(2-Hydroxyphenyl)-2-methyl-5-oxo-5,6-dihydro-1H-imidazo[1,2-b][1,2,4]triazol-3(2H)-
yl)-3-(1H-indol-2-yl)propanoic acid 3d. Anal. calcd. for C22H21N5O4 (Mr = 419.43): C, 62.94; H, 
5.06; N, 16.68. Found: C, 62.65; H, 5.10; N, 16.42.IR (, cm-1); 3408 (broad O–H), 3321 (O–H), 
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3202, 3136 (2NH), 3050 (C–H) aromatic, 2976 (C–H) aliphatic, 1710 (C=O), 1616 (COOasy), 
1586 (COOsy), 1233 (Ph–O). 1H NMR (400 MHz; d6-DMSO, ppm); 2.55 (S, 3H, CH3), 3.86 
(d, 2H, CH2), 4.09 (s, 1H, CH-COOH), 4.1 (s, 2H, CH2), 5.14 (s, 2H, OH, NH, disappeared by 
D2O), 6.91-7.66 (m, 8H, ArH), 14.24 (s, 1H, OH, disappeared by D2O). 
13CNMR: 24.81 (CH3), 
30.22 (CH2), 33.33 (CH2), 54.01 (CH), 117.47, 118.86, 122.23, 123.11, 125.76, 126.22, 126.86, 
128.87, 132.20, 133.44. 136.76, 138.22 (ArC), 153.66 (C=N), 168.22 (C=O), 174.10 (C=O). 
 
General procedure for synthesis of compounds 4b,d  
 
To a solution of 2-amino-5(2-hydroxy phenyl)-1,2,4-triazole carboxylic acid 1a,d (0.01 mol) 
and 4-chlorobenzoyl chloride (1.28 mL, 0.01 mol) in chloroform and a catalytic amount of 
triethylamine as a catalyst. The reaction component was refluxed for 7 hrs to complete the 
reaction (monitored by TLC). After completion of the reaction, mixture was cooled to room 




acid 4b. Anal. calcd. for C18H17ClN4O4 (Mr = 388.80): C, 55.60; H, 4.41; N, 14.41; Cl, 9.12. 
Found: C, 56.70; H, 4.32; N, 14.25 ; Cl, 9.08.IR (, cm-1); 3412 (broad O–H), 3268 (NH), 3171 
(NH), 3071 (C–H) aromatic, 2991 (C–H) aliphatic, 1732 (C=O), 1612 (COOasy), 1589 (C=N), 
1513 (COOsy), 1255 (Ph–O). 1H NMR (400 MHz; d6-DMSO, ppm); 2.22 (d, 3H, CH3), 2.58 
(s, 3H, CH3), 3.37 (m, 1H, CH-COOH), 7.35-8.23 (m, 8H, 2ArH), 8.23 (s, 1H, OH, 
exchangeable by D2O), 9.17 (s, 1H, NH, disappeared by D2O), 10.21 (s, 1H, OH, disappeared by 
D2O). 
13CNMR: 18.04 (CH3), 37.86 (CH3), 61.94 (C-triazole), 118.45, 122.23, 123.84, 126.55, 
128.45, 132.50. 134.67, 141.20, 143.44, 144.29 (ArC), 152.35 (CH=N), 164.33 (C-OH), 179.47 
(C=O), 198.56 (C=O).  
 
2-(3-(4-Chlorobenzamido)-5-(2-hydroxyphenyl)-5-methyl-1H-1,2,4-triazol-4(5H)-yl)-3-(1H-
indol-2-yl)propanoic acid 4d. Anal. calcd. for C27H24ClN5O4 (Mr = 517.96): C, 62.61; H, 4.67; 
N, 13.52; Cl, 6.84. Found: C, 62.45; H, 4.55; N, 13.35 ; Cl, 6.62. IR (, cm-1); 3437 (broad O–
H), 3315 (OH), 3162, 3111 (2NH), 3018 (C–H) aromatic, 2987 (C–H) aliphatic, 1703 (C=O), 
1606 (COOasy), 1587 (C=N), 1536 (COOsy), 1227 (Ph–O). 1H NMR (400 MHz; d6-DMSO, 
ppm); 2.24 (s, 3H, CH3), 3.25, 3.49 (dd, 2H, CH2), 3.62 (t, 1H, CH-COOH), 4.49 (s, 1H, CH-
indole), 6.98-8.13 (m, 12H, 3ArH), 8.65 (s, 1H, NH, disappeared by D2O), 10.11 (s, 1H, OH, 
exchangeable by D2O), 10.87 (s, 1H, NH, disappeared by D2O),  10.90 (s, 1H, NH, disappeared 
by D2O), 12.91(s, 1H, OH, exchangeable by D2O). 
13CNMR: 19.39 (CH3), 26.23 (CH2), 56.24 
(CH-COOH), 61.94 (C-triazole), 111.79 (CH-indole), 117.02, 118.22, 122,34, 123.44, 124.43, 
126.32, 126.88, 128.22, 1,32.11, 133.45, 134,67, 136.74, 138.55, 141.22, 142.21, 143.11 (ArC), 
156.91 (C=N), 164.89 (C-OH), 173.78 (C=O), 180.56 (C=O). MS (m/z+, %): 515.20 (M-2, 0.04); 
481 (0.05), 437 (0.17), 317 (1.78); 201 (5.20); 175.10 (3.70); 159.15 (5.62), 130.15 (24.08); 
103.10 (10.07); 59 (100). 
 
General procedure for synthesis of compounds 5a, 6a 
 
Method A. 2-Amino-5(2-hydroxy phenyl)-1,2,4-triazole carboxylic acid  1a (0.01 mol) was 
dissolved in 3 mL thionyl chloride and kept for 24 hrs at room temperature. After completion of 
the reaction, the mixture was poured into petroleum ether drop-wise and the solid mass was 
filtered off and recrystallized from ethanol into compound 5a. 
 
Method B. An equimolar mixture of 2-amino-5(2-hydroxy phenyl)-1,2,4-triazole carboxylic acid  
1a (0.01 mol) and thionyl chloride (1.2 g, 0.01 mol) was dissolved in 3 mL DMF. The reaction 
mixture was refluxed for 3 hrs (as monitored by TLC). After completion of the reaction, mixture 
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was poured into ice and the solid mass was filtered off and recrystallized from ethanol into 
compound 6a. 
 
2-(3-Amino-5-(2-hydroxyphenyl)-1H-1,2,4-triazol-4(5H)-yl)propanoyl chloride 5a. Anal. calcd. 
for C11H13Cl N4O2 (Mr = 268.70): C, 49.17; H, 4.88; N, 20.85; Cl, 13.19. Found: C, 49.77; H, 
4.78; N, 20.51; Cl, 13.05. IR (, cm-1); 3353 (OH), 3224, 3136, 3024 (NH, NH2), 3010 (C–H) 
aromatic, 2929 (C–H) aliphatic, 1653 (C=O), 1584 (C=N), 1269 (Ph–O). 1H NMR (400 MHz; 
d6-DMSO, ppm); 1.04 (d, H, CH3), 3.47 (s, 1H, CH-triazole), 3.65 (q, 1H, CH-COOH), 6.17 (s 
broad, 3H, NH2, OH, exchangeable by D2O), 7.42-8.07 (m, 4H, ArH) 8.82 (s, 1H, NH, 
exchangeable by D2O). 
13CNMR: 18.04 (CH3), 57.35 (CH), 62.31 (CH-triazole), 118.67, 122.89, 
123.55, 126.76. 130.84, 133.29 (ArC), 154.23 (C=N), 167.47(C=O).  
 
3-(2-Hydroxyphenyl)-5-methyl-5,7-dihydro-2H-imidazo[2,1-c][1,2,4]triazol-6(3H)-one 6a. 
Anal. calcd. for C11H12N4O2 (Mr = 232.24): C, 56.89; H, 5.21; N, 24.12. Found: C, 56.35; H, 
5.65; N, 23.99. IR (, cm-1); 3370 (OH), 3243, 3179 (2NH), 3040 (C–H) aromatic, 2970 (C–H) 
aliphatic, 1661 (C=O), 1584 (C=N), 1269 (Ph–O). 1H NMR (400 MHz; d6-DMSO,  ppm); 1.06 
(d, H, CH3), 3.46 (s, 1H, CH-triazole), 5.02 (q, 1H, CH-imidazole), 6.96-7.11 (m, 4H, ArH), 
10.27, 10.71, 11.13 (s, 3H, 2NH, OH, exchangeable by D2O ). 
 
General method for preparation of 7a, c, d, e 
 
An equimolar of 2-amino-5(2-hydroxy phenyl)-1,2,4-triazole carboxylic acid  1a, c, d , e 
(0.01 mol) and 5 mL Acetic anhydride in presence of few drops of pyridine. The reaction was 
refluxed for 2-4 hrs (monitored by TLC). After completion of the reaction, the mixture was 
poured into ice and the solid mass of the compounds was filtered and recrystallized from 
ethanol. 
 
2-(3-acetamido-5-(2-hydroxyphenyl)-1H-1,2,4-triazol-4(5H)-yl)propanoic acid 7a. Anal. calcd. 
for C13H16N4O3 (Mr = 292.29): C, 53.37; H, 5.47; N, 19.16. Found: C, 52.97; H, 5.16; N, 18.93. 
IR (m, cm-1); 3218 (O-H), 3224, 3149 (2NH), 3067 (C–H) aromatic, 2930, 2870 (C–H) 
aliphatic, 1689 (C=O), 1663 (C=N), 1612 (COOasy), 1486 (COOsy), 1179 (C-O), 1280 (Ph–O). 
1H NMR (400 MHz; d6-DMSO, ppm); 2.05 (d, 3H, CH3), 2.22 (s, 3H, COCH3), 2.55 (t, 1H, CH-
COOH), 4.32 (s, 1H, CH-triazole), 7.05-7.32 (m, 4H, ArH), 7.94 (s, 1H, NH, disappeared by 
D2O), 11.60 (s, 1H, NH, disappeared by D2O), 11.97 (s, 1H, OH, exchangeable by D2O), 14.22 
(s, 1H, OH, exchangeable by D2O). 
13CNMR; 21.23 (CH3), 22.87 (COCH3), 43.26 (CH-COOH), 
53.52 (CH-triazole), 118.78, 122.35, 124.89, 126.66, 132.34, 134.29 (ArC), 148.33 (C=N), 
168.67(C=O), 172.28 (C=O). MS (m/z+, %): 292.20 (M+1, 5.95); 291 (6.39); 278 (26.09); 247 
(3.93); 236 (44.03); 194.10 (11.07);  117.10 (20.57); 59 (100). 
 
2-(3-Acetamido-5-(2-hydroxyphenyl)-1H-1,2,4-triazol-4(5H)-yl)-3-(1H-indol-2-yl)propanoic 
acid 7c. Anal. calcd. for C21H21N5O4 (Mr = 407.42): C, 61.88; H, 5.15; N, 17.81. Found: C, 
61.54; H, 5.20; N, 17.55. IR (KBr, , cm-1); 3303 (O–H), 3230, 3188 (2NH), 3142 (NH indole), 
3059 (C–H) aromatic, 2927 (C–H) aliphatic, 1695 (C=O), 1641 (C=N), 1620 (COOasy), 1487 
(COOsy), 1188 (C–O). 1H NMR (400 MHz; d6-DMSO,  ppm): 1.92 (s, 3H, COCH3), 2.01, 
2.19 (dd, 2H, CH2), 2.25-2.33 (t, 1H, CH-COOH), 5.19 (s, 1H, CH-triazole), 6.82 (s, 1H, CH-
indole), 6.97-7.54 (m, 8H, 2ArH), 8.88 (s, 1H, NH, exchangeable by D2O), 9.66 s, 1H, OH, 
disappeared by D2O), 11.81 (s, 1H, OH, exchangeable by D2O), 11.99 (s, 1H, NH, disappeared 
by D2O). 
13CNMR: 22.21 (COCH3), 26.83 (CH2), 39.55 (CH-COOH), 53.48 (CH-triazole), 
112.22 (CH-indole), 118.86, 122.55, 123.44, 124.79, 132.33, 133.74 (ArC), 149.24 (C=N), 
168.22 (C=O), 172.72 (C=O). 
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2-(3-Acetamido-5-(2-hydroxyphenyl)-5-methyl-1H-1,2,4-triazol-4(5H)-yl)-3-(1H-indol-2-yl)pro- 
panoic acid 7d. Anal. calcd. for C22H23N5O4 (Mr = 421.45): C, 62.64; H, 5.45; N, 16.60. Found: 
C, 62.44; H, 5.20; N, 16.95. IR (KBr, , cm-1); 3461 (O–H), 3311, 3180 (2NH), 3142 (NH-
indole), 3066 (C–H) aromatic, 2989 (C–H) aliphatic, 1698 (C=O), 1632 (C=N), 1607 
(COOasy), 1486 (COOsy), 1173 (C–O). 1HNMR (400 MHz; d6-DMSO,  ppm): 1.92 (s, 3H, 
COCH3), 2.06, 2.20 (dd, 2H, CH2), 2.30 (s, 3H, CH3), 2.85 (t, 1H, CH-COOH), 6.89 (s, 1H, CH-
indole), 6.98-7.58 (m, 8H, 2ArH), 7.61 (s, 1H, NH, exchangeable by D2O), 8.18 (s, 1H, NH, 
exchangeable by D2O), 11.81 (s, 1H, OH, exchangeable by D2O), 11.97 (s, 1H, NH, disappeared 
by D2O). 
13CNMR: 21.43 (CH3), 22.24 (COCH3), 25.23 (CH2), 43.26 (CH-COOH), 62.65 (C-
triazole), 123.22 (CH-indole), 118.66, 121.32, 122.50, 123.79, 124.62, 126.55, 127.32, 128.45, 
132.98, 132.61, 133.74 (ArC), 148.70 (C=N), 168.03 (C=O), 172.28 (C=O). 
 
2-(3-Acetamido-5-(2-hydroxyphenyl)-1H-1,2,4-triazol-4(5H)-yl)-3-(1H-imidazol-5-yl)propanoic 
acid 7e. Anal. calcd. for C16H18N6O4 (Mr = 358.35): C, 53.58; H, 5.02; N, 23.44. Found: C, 
53.33; H, 5.21; N, 23.22. IR (KBr, , cm-1); 3362 (O–H), 3234, 3187 (2NH), 3132 (NH-
imidazole), 3061 (C–H) aromatic, 2968 (C–H) aliphatic, 1687 (C=O), 1612 (C=N), 1561 
(COOasy), 1446 (COOsy), 1186 (C–O). 1HNMR (400 MHz; d6-DMSO,  ppm): 1.87 (s, 3H, 
COCH3), 2.05, 2.26 (dd, 2H, CH2), 3.44 (t, 1H, CH-COOH), 4.24 (s, 1H, CH-triazole), 7.10-
7.81 (m, 6H, ArH + 2CH-imidazole),7.68  (s, 1H, OH, disappeared by D2O), 8.27 (s, 1H, NH, 
exchangeable by D2O), 11.56 (s, 1H, NH indole, disappeared by D2O), 11.77 (s, 1H, OH, 
disappeared by D2O). 
13CNMR: (400 MHz; d6-DMSO,  ppm): 21.24 (COCH3), 28.53 (CH2), 
56.52 (CH-COOH), 76.05 (CH-triazole), 123.85, 134.22 (2CH-imidazole), 118.80, 122.23, 
126.86, 132.85, 133.35 (ArC), 153.90 (C=N), 168.69, 169.78 (CO), 181.82 (C=O). 
 
RESULT AND DISCUSSION 
 
The starting material amino acid coupled triazoles 1a-e [29] were allowed to react with different 
reagents such as acid chloride derivatives, thionyl chloride acetic anhydride then a comparative 
study of the antileishmanial activity was achieved on the synthesized compounds searching for 
structure-activity relationship information to support the development of new drug candidates 
for Leishmanial aethiopica promastigotes (Table 1). 
 
Table 1. Characterization data of amino acid coupled triazole derivatives (1a-e). 
 
Compound No. R1 R2 M.P. (°C) Yield (%) 
1a H -CH3 267 52 





















The reaction of compounds 1a,b and 1d with chloroacetyl chloride in acetonitrile/water as a 
solvent and in the presence of potassium carbonate as catalyst (method A) afforded the 
unexpected products imidazo-1,2,4-triazole 2a,b. The reaction mechanism of formation of the 
unexpected products 2a,b was suggested to proceed via acetylation of amino group in first step 
then a preliminary elimination of an acid molecule followed by tautomerization and cyclization, 
Scheme 1. 
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The structures of the synthesized compounds were assigned based on spectral data (IR, 1H-
NMR, 13C-NMR, MS) and elemental analysis. IR spectra of compounds 2a,b showed new peak 
owing to the new carbonyl group of imidazole ring located at 1695 and 1713 cm-1, respectively. 
1H-NMR spectra showed the presence of protons of R1 where noted singlet signal at 3.99 ppm 
for CHtriazole group in case of compound 2a, also singlet signal at 2.43 ppm for CH3 group in case 
of compound 2b. Moreover, showed disappearance of protons of R2, CH and COOH groups 
which noted in starting compound, in addition to the existence of new singlet signal of CH2 
group of imidazole ring at 3.92 and 4.02 ppm corresponding to compound 2a and 2b, 
respectively. 13C-NMR spectrum showed the disappearance of signal of carbonyl group of 
carboxylic acid group and appearance of new carbonyl group of imidazole ring at 170.10 and 
186.94 ppm, respectively. 
Reaction of compound 1b with chloroacetyl chloride in chloroform in presence of a catalytic 
amount of triethylamine (method B) afforded the corresponding 5-oxoimidazo-1,2,4-triazole-
propanoic acid 3b (Scheme 2). Where IR spectrum of compound 3b illustrated the appearance 
of new peaks at 1714 cm-1corresponding to the carbonyl group, 1H-NMR showed the presence 
of two CH3 groups and CH2 group at 2.55, 3.86 and 4.01 ppm and 
13C-NMR spectrum showed 
the appearance of two signals of two carbonyl groups at 169.27 and 174.13 ppm. Also, the 
reaction of compound 1b and 1d with 4-chlorobenzoyl chloride in chloroform in the presence of 
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few drops of triethylamine gave the corresponding N-aryl derivatives 4b and 4d. The IR spectra 
showed the presence of new peak of carbonyl group of carbonyl acid. 1H-NMR illustrated 
increase the protons number due to the phenyl group of chlorobenzoyl chloride. 13C-NMR 
spectrum of compound 4b showed appearance of two signals of two carbonyl groups at 179.47 








Moreover, compound 1a could react with thionyl chloride in different conditions: at room 
temperature afforded the corresponding 2-[3-Amino-5-(2-hydroxy-phenyl)-1,5-dihydro-
[1,2,4]triazol-4-yl]-propionyl chloride 5a. Under reflex, the reaction of the titled compound 1a 
with thionyl chloride in dimethylformamide gave 2,3-dihydro-3-(2-hydroxyphenyl)-5-methyl-
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5H-imidazo[2,1-c][1,2,4]triazol-6(7H)-one 6a, Scheme 3. As observed from IR spectra the 
disappearance of COOH group and appearance of C=O group at 1637 cm-1 in case of compound 
5a and at 1701 cm-1 in case of compound 6a. 1H-NMR and 13C-NMR spectra confirmed the 
suggested structure of the obtained compounds, Scheme 3. 
Acetylation reaction of 1,2,4-triazole-3-carboxylic acid derivatives 1a, c,d,g with acetic 
anhydride in presence of few drops of pyridine gave N-acetylacetamido-1,2,4-triazol-4(5H)-
propanoic acid  7a,c,d,e Scheme 4. IR spectrum illustrated the appearances of new carbonyl 
group owing to acetyl group. 1H-NMR spectrum of compounds 7a,c,d,e showed singlet signals 
of acetyl group at 2.22, 1.92, 1.87 and 1.92 ppm, respectively. 13C-NMR of these compounds 
observed two signals of carbonyl group, one of carboxylic acid and the other for acetyl groups 




In vitro anti leishmanial activity on Leishmanial aethiopica promastigotes 
The Alamar blue indicator (oxidation-reduction®) was enhanced to mensuration cytotoxicity of 
new heterocyclic compounds against the protozoan parasite L.aethiopica by using a quantitative 
colorimetric method. Alamar blue assay was used to measure the viability of promastigotes and 
determine the ant leishmanial activity of the synthesized compounds [30-34] (supporting 
information). To evaluate the ant leishmanial activity of the synthesized compounds, a final 
concentration of 1 mg/mL of synthesized compounds dissolvedin DMSO. There are no effects 
on parasite when the final concentration of DMSO did not exceed 0.1%. Test and standard 
solutions were diluted to suitable concentrations using fresh complete media. The test 
compounds were prepared by three-fold serial dilutions (starting from 10 to 0.04 mg/mL) 
The test compounds were used in three-fold serial dilutions to evaluate its antileishmanial 
activity according to Amphotericin B deoxycholate and miltefosine were used as positive 
controls for comparison. Promastigote type of L. aethiopica was used for the assay. A 100 mL 
of culture media containing 3x106 promastigotes of L. aethiopica were seeded in each well of a 
96 well flat bottom plate. Different dilutions of test compounds (10, 3.33, 1.11, 0.37, 0.12, 0.04 
mg/mL) were added to the parasites. The assay was done in duplicates. The parasites existed 
only in wells; media and DMSO were used as negative control. The plates were remained at 
room temperature (21±1 oC). After 24 h, 10 mL wasadded to each of the wells of Alamar blue 
(12.5 mg resazurin dissolved in 100 mL of distilled water) [32]. After 48 h, absorbance of the 
resulting mixture was measured at 540 and 630 nm using a plate reader. Alamar blue works 
through the conversion of resazurin (7-hydroxy-3H-phenoxazine-3-one-10-oxide), the active 
ingredient of Alamar blue® (blue and non-fluorescent), to resorufin (pink and highly 
fluorescent) through reduction reactions of metabolically active cells. There is a proportional 
relationship between the amount of fluorescence produced and the number of living cells. 
All the synthesized compounds had IC50 better than standard drugs miltefosine and 
comparative activity to amphotericin B deoxycholate. The lead compound 7d showed more 
activity than amphotericin B and about 110 folds than miltefosine. Moreover, compounds 2b 
and 7e showed similar activity to amphotericin Band high activity to miltefosine, which 
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indicates its ant leishmanial activity against L. aethiopica. In deeps, compounds 
showed low activity corresponding
L. aethiopica promastigotes (Table 2). The bar chart (Fig
the tested compound comparing to reference drugs.















Figure 1. The test compounds showed the highest antileishmanial activity, compared with the 
reference.   
In vivo acute toxicity testing 
The most active ant leishmanial compounds, 
(supporting information) [35, 
treatment with the test compounds. There was no significant difference in the weight of the mice 
and no death cases were recorded during 3 days of observation post administration of the test 
compounds (Table 2). The test compounds were well tolerated by the experimental animals 
orally up to 250 mg/kg. Eleven groups of mice, each group consisting of six male mice (25
g) were used for testing acute toxicity [30]. The mice in each group were fasted overnight and 
weighed prior to test. The compounds were prepared in suspension form in aqueous vehicle 
containing 1% gum acacia. Mice in group one to ten were given 25, 50, 100, 20
of the synthesized compounds as a single dose for only one day, while the eleventh group was 
treated orally with the vehicle gum acacia (control group) at a maximum dose of 1 mL/100 g of 
body weight. The mortality percentage in each group w
test compounds were investigated for their parenteral acute toxicity in groups of six mice each 
as reported earlier. The compounds, or their vehicle, propylene glycol (control), were given by 
intraperitoneal injection in doses of 10, 25, 50, 75, 100 mg/kg. The survival percentage was 
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2b, 7d and 7e were tested for their toxicity in mice 
36]. The experimental mice did not have any toxicity signs after 
0 and 350 mg/kg 





Ahmed M. M. El-Saghier et al. 
Bull. Chem. Soc. Ethiop. 2018, 32(3) 
568
Molecular docking 
In the present study, molecular docking was performed to rationalize the obtained biological 
results. The interactions of the synthesized compounds with the active site of target 
macromolecules were investigated to study the mode of binding and their orientations and 
related to their ant leishmanial activity. The binding site of Leishmania major pteridine 
reductase LmPTR1 (PDB ID: 2BFM) was explored computationally, were carried out using 
Molecular Operating Environment (MOE Dock 2016) software [37]. The crystal structure of 
LmPTR1 with the bound TOP (PDB ID: 2BFM) was downloaded from the protein data bank. 
PTR1 represents a target for the development of improved therapies for infections caused by this 
protozoan. Target compounds were constructed using the builder interface of the MOE program 
and all hydrogens were added. Conformational analyses were done through energy minimization 
using Force Field MMFF94x. The active sites of both proteins were generated using the MOE- 
Alpha Site Finder, and then ligands were docked within this active site using MOE Dock. 
 
Figure 2. Docking of compound 2b.  
For example, the determination of three dimensional cocrystal structure of LmPTR1 
complex with 3-(2-hydroxyphenyl)-3-methyl-3H-imidazo[2,1-c][1,2,4]triazol-6(5H)-one 2b 
(trimethoprim, TOP) showed hydrogen bond interaction with Ser 111 as well as hydrophobic 
interactions with Lys 198 and other amino acid residues (Figure 2).  
CONCLUSION 
The objectives of the present study were to synthesize, characterized and investigate the ant 
leishmanial activities of some imidazo-1,2,4-triazole moiety  serving as more potent dual ant 
leishmanial agents. The in vitro anti promastigote activity showed that IC50 value of compounds 
2b, 6a, 7a, 7c and 7e better than standard drugs miltefosine and comparative activity to 
amphotericin B deoxycholate. The superior compound 7d showed more activity than 
amphotericin B and about 110 folds more active than miltefosine. These findings were 
supported by the docking for 2b compound, which demonstrated that this compound established 
hydrogen bonding with some amino acid residues in LmPTR1 active site, which showed good 
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binding profile in addition to some hydrophobic interactions with good scoring results. Toxicity 
studies for the most active compounds indicated their safety orally and parenterally up to 300 
and 100 mg/kg, respectively. In conclusion, compounds 2b, 7d and 7e demonstrated dual 
activity against leishmania and represent fruitful scaffolds for the development of dual acting 
ant leishmanial agents. 
REFERENCES 
 
1. Valdivia, H.O.; Reis-Cunha, J.L.; Rodrigues-Luiz, G.F.; Baptista, R.P.; Baldeviano, G.C.; 
Gerbasi, R.V. Comparative genomic analysis of Leishmania (Viannia) peruviana and 
Leishmania (Viannia) braziliensis. BMC Genomics 2015, 16, 715–725.  
2. Bates, P.A. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand 
flies. Int. J. Parasitol. 2007, 37, 1097–1106. 
3. WHO (World Health Organization). Leishmaniasis-Fact Sheet. Available online: 
http://www.who.int/mediacentre/factsheets/fs375/en/, accessed on April 2017. 
4. Sundar, S.; Murray, H.W. Availability of miltefosine for the treatment of Kala-Azar in India. 
Bull. World Health Organ. 2005, 83, 394–395. 
5. Rakotomanga, M.; Saint-Pierre-Chazalet, M.; Loiseau, P.M. Alteration of fatty acid and 
sterol metabolism in miltefosine-resistant Leishmania donovanipromastigotes and
 consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 2005, 49, 
2677–2686. 
6. Kulkarni, M.M.; Reddy, N.; Gude, T.; McGwire, B.S. Voriconazole suppresses the growth 
of Leishmania species in vitro. Parasitol. Res. 2013, 112, 2095–2099. 
7. Freitas-Junior, L.H.; Chatelain, E.; Kim, H.A.; Siqueira-Neto, J.L. Visceral leishmaniasis 
treatment: What do we have, what do we need and how to deliver it? Int. J. Parasitol. Drugs 
Drug Resist. 2012, 2, 11–19. 
8. Goad, L.J.; Berens, R.L.; Marr, J.J.; Beach, D.H.; Holz, J.G.G. The activity of ketoconazole 
and other azoles against Trypanosoma cruzi: Biochemistry and chemotherapeutic action in 
vitro, Mol. Biochem. Parasitol. 1989, 32, 179–189. 
9. Hernández-Chinea, C.; Carbajo, E.; Sojo, F.; Arvelo, F.; Kouznetsov, V.V.; Romero-
Bohórquez, A.R.; Romero, P.J. In vitro activity of synthetic tetrahydroindeno[2,1-c] 
quinolines on Leishmania Mexicana. Parasitol. Int. 2015, 64, 479–483. 
10. Khademvatan, S.; Gharavi, M.J.; Rahim, F.; Saki, J. Miltefosine-induced apoptotic cell 
death on Leishmania major and L. tropica strains. Korean J. Parasitol. 2011, 49, 17–23. 
11. Klug, D.M.; Gelb, M.H.; Pollastri, M.P. Repurposing strategies for tropical disease drug 
discovery. Bioorg. Med. Chem. Lett. 2016, 26, 2569–2576. 
12. Beach, D.H.; Goad, L.J.; Holz, Jr., G.G. Effects of antimycotic azoles on growth and sterol 
biosynthesis of Leishmania promastigotes. Mol. Biochem. Parasitol. 1988, 31, 149–162. 
13. Albanese, G.; Giorgetti, P.; Santagostino, L.; Crippa, D.; Sala, G. Cutaneous leishman-iasis: 
Treatment with itraconazole. Arch. Dermatol. Res. 1989, 125, 1540–1542. 
14. Al-Abdely, H.M.; Graybill, J.R.; Loebenberg, D.; Melby, P.C. Efficacy of triazole 
SCH56592 against Leishmania amazonensis and Leishmania donovani in experi-mental 
murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother. 1999, 43, 
2910–2914. 
15. Alrajhi, A.A.; Ibrahim, E.A.; De Vol, E.B.; Khairat, M.; Faris, R.M.; Maguire, J.H. 
Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New 
Engl. J. Med. 2002, 346, 891–895. 
16. Baron, S.; Laube, S.; Raafat, F. Moss C. Cutaneous leishmaniasis in a Kosovan child treated 
with oral fluconazole. Clin. Exp. Dermatol. 2004, 29, 545–62. 
17. Nassiri-Kashani, M.; Firooz, A.; Khamesipour, A.; Mojtahed, F.; Nilforoushzadeh, M.; 
Hejazi, H.; Bouzari, N.; Dawlati, Y. A randomized, double-blind, placebo-controlled clinical 
trial of itraconazole in the treatment of cutaneous leishmaniasis. J. Eur. Acad. Dermatol. 
Venereol. 2005, 19, 80–83. 
18. Rafaa, M.; Ingen-Housz-Oro, S.; Méry, L.; LeTurdu, F.; Wendlig, J.; Pauwels, C.; Sigal-
Grinberg, M. Traitement par fluconazole de la leishmaniose cutanée chez l’enfant. Ann. 
Dermatol. Venereol. 2007, 134, 682–687. 
Ahmed M. M. El-Saghier et al. 
Bull. Chem. Soc. Ethiop. 2018, 32(3) 
570
19. Sklavos, A.V.; Walls, T.; Webber, M.T.; Watson, A.B. Cutaneous leishmaniasis in a child 
treated with oral fluconazole. Australas J. Dermatol. 2010, 51, 195–197. 
20. Daly, K.; Lima, H.D.; Kato, H.; Sordillo, E.M.; Convit, J.; Reyes-Jaimes, O.; Paniz-
Mondolfi, A.E. Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) 
braziliensis successfully treated with fluconazole. Clin. Exp. Dermatol. 2014, 39, 708–712. 
21. Elmahallawy, E.K.; Agil, A. Treatment of leishmaniasis: A review and assessment of recent 
research. Clin. Infect. Dis. 2015, 60, 1398–1404. 
22. Aouali, M.; Allouche, F.; Zouari, I.; Mhalla, D.; Trigui, M.; Chabchoub, F. Synthesis, 
antibacterial, and antifungal activities of imidazo[2,1-c][1,2,4]triazoles and 1,2,4-
triazolo[4,3-a]pyrimidinones. Int. J. Rapid Commun. Synth. Org. Chem. 2014, 44, 748–756.  
23. Huang, Y.; Xiu-Qin, H.; Da-Peng, Sh.; Yong-Fei, C.; Peng-Fei, X. Synthesis of 1H-
imidazo[1,2-b]-1,2,4-triazol-6-aminesvia multicomponent reaction. Mol. Divers. 2007, 11, 
73–80.  
24. Sztanke, K.; Pasternak, K.; Sidor-Wójtowicz, A.; Truchlińska, J.; Jóźwiak, K. Synthesis of 
imidazoline and imidazo[2,1-c][1,2,4]triazole aryl derivatives containing the methylthio 
group as possible antibacterial agents. Bioorg. Med. Chem. 2006, 14, 3635–3642.   
25. Seelama, S.N.; Shrivastava, P.; Prasanthi, S.; Gupta, S. Synthesis and in vitro study of some 
fused 1,2,4-triazole derivatives as antimycobacterial agents. J. Saudi Chem. Soc. 2016, 20, 
411-418.  
26. Aouali, M.; Dhekra, M.; Allouche, F.; El Kaim, L.; Tounsi, S.; Trigui, M.; Chabchoub, F. 
Synthesis, antimicrobial and antioxidant activitiesof imidazotriazoles and new 
multicomponent reactiontoward 5-amino-1-phenyl[1,2,4]triazole derivatives. Med. Chem. 
Res. 2015, 24, 2732–2741.  
27. Chidananda, N.; Poojary, B.; Sumangala, V.; Suchetha Kumari, N.; Shetty, P.; Arulmoli, T. 
Eur. J. Med. Chem. 2012, 51, 124–136. 
28. Mast, N.; Zheng, W.; Stout, C.D.; Pikuleva, I.A. Antifungal azoles: Structural insights into 
undesired tight binding to cholesterol-metabolizing CYP46A1. Mol. Pharmacol. 2013, 84, 
86–94. 
29. Bekhit, A.A.; Ibrahim, T.; Mohamed, M.A.A.; Abdel-Aziz, O.A.; Kadry, A.M.; El-Saghier, 
A.M.M. Green synthesis, antileishmanial activity evaluation, and in silico studies of new 
amino acid coupled 1,2,4-triazoles. Bioorg. Med. Chem. 2018, in press. 
30. Lara, O.; Raquel, E.; María, A.; Juan, J.; Francisco, B.; José, M. In vitro effect of new 
formulations of amphotericin B on amastigote and promastigote forms of Leishmania 
infantum. Int. J. Antimicrob Agents 2007, 30, 325–329.  
31. Dorlo, T.P.C.; Kager, P.A. Comment on: Cutaneous and mucocutaneous leishmaniasis in 
Tigray, northern Ethiopia: Clinical aspects and therapeutic concerns. Trans. Royal Soc. 
Trop. Med. Hyg. 2010, 104, 84–85.  
32. Jorda, R.; Sacerdoti-Sierra, N.; Voller, J.; Havlícek, L.; Kracalíkova, K.; Nowicki, M.W.;  
Nasereddin, A.; Krystof, V.; Strnad, M.; Walkinshaw, M.D.; Jaffe, C.L. Anti-leishmanial 
activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines. Bioorg. Med. Chem. 
Lett. 2011, 21, 4233-4237. 
33. Shimony, O.; Jaffe, C.L. Rapid fluorescent assay for screening drugs on Leishmania 
amastigotes. J. Microbiol. Methods 2008, 75, 196–200. 
34. Corral, M.J.; Gonzalez, E.M.; Cuquerella, J.M.; Alunda, J. Improvement of 96-well 
microplate assay for estimation of cell growth and inhibition of Leishmania with Alamar 
Blue. J. Microbiol. Methods 2013, 94, 111–116. 
35. Bekhit, A.A.; Hymete, A.; Asfaw, H.; Bekhit, A.E.-D. Synthesis and biological evaluation 
of some pyrazole derivatives as anti-malarial agents. Arch. Pharm. Chem. Life Sci. 2012, 
345, 147–154. 
36. Habib, N.S.; Farghaly, A.M.; Ashour, F.A.; Bekhit, A.A.; Abd El Razik, H.A.; Abd 
ElAzeim, T. Synthesis of some triazolophthalazine derivatives for their anti-inflammatory 
and antimicrobial activities. Arch. Pharm. Chem. Life Sci. 2011, 344, 530-542. 
37. Molecular Operating Environment (MOE), Version, Chemical Computing Group, Inc.: 
Montreal, Canada; 2016.  
